Aptose Biosciences Inc. announced that it has entered into a subscription agreement with returning investor, Hanmi Pharm. Co., Ltd. to issue 2,105,263 common shares at an issue price of $1.19 per share and 2,339,181 warrants for the gross proceeds of $3,999,999.7on January 25, 2024. The common shares and warrants will be sold in combination, with one common share and 1.11111106 warrant comprising each combined security set purchased by investor.

The purchase price for each combined set of one common share and 1.11111106 warrants will be $1.90. Each whole warrant will be exercisable for one common share at an exercise price of $1.71 per common share until the date that is five years from the date of issuance. Hanmi Pharm.

Co., Ltd. is a current shareholder of company and holds, as of the date of this current report, approximately 884,152 common shares, which represents approximately 11.1% of our issued and outstanding common shares. Following completion of the investment and the offering, the investor will beneficially hold approximately 19.99% of our issued and outstanding common shares. In connection with the completion of the transaction, Hanmi Pharm.

Co., Ltd.'s obligation to fund the second tranche of its investment pursuant to the subscription agreement entered by Aptose Biosciences Inc. and investor on September 6, 2023, will be deemed to be satisfied.